Xiclovir

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xiclovir

Property Description
Active Ingredient Aciclovir (Acyclovir)
Pharmacological Class Antiviral Agent (Antiherpetic)
Origin Synthetic Compound (Guanosine Nucleoside Analog)
Common Forms Tablet, Capsule, Oral Suspension, Cream
Administration Systemic (Oral/IV) and Topical

What Type of Medicine is Xiclovir?

Xiclovir is the medicinal entity whose active ingredient, Aciclovir, is classified as a synthetic antiviral agent and a specialized antiherpetic drug. Chemically, Aciclovir is a synthetic compound derived as a guanosine nucleoside analog, which places it within the broader group of purine analogs. This classification establishes its highly targeted nature, distinguishing it from broad-spectrum antimicrobials. The drug's synthetic origin means it was precisely engineered to interfere with specific processes unique to the target viral life cycle, and it is typically designated as a prescription-only medicine (Rx).


Composition and Available Forms of Aciclovir

The core composition of Xiclovir is the single active ingredient, Aciclovir, which is formulated to allow both systemic administration and topical administration as required. This monocomponent drug is available in multiple dosage forms, including tablets, capsules, and oral suspension for systemic use, and cream or ophthalmic ointment for localized application. Aciclovir is characterized by its high specificity against certain viruses. To create these forms, Aciclovir is combined with various pharmaceutical vehicles, such as solid excipients for oral forms, aqueous solutions for injectable forms, and emollient bases for topical application.


What is the General Purpose of This Antiviral Agent?

The primary purpose of Xiclovir is to limit the extent and duration of certain viral infections by acting as a virostatic agent, which means it halts viral growth rather than destroying the virus directly. This is achieved through a mechanism focused on viral replication disruption; the substance interferes with the virus's ability to copy its genetic code, preventing it from multiplying and spreading to healthy cells. By blocking the viral growth cycle, the medication effectively controls the spread of the pathogen, thereby giving the body's immune system the necessary advantage to clear the existing infection. Its general therapeutic purpose is recognized as a standard of care for addressing the proliferation of specific viral pathogens.

Regulatory References

  1. WHO Essential Medicines List (eEML) for Aciclovir
  2. NIH MedlinePlus Drug Information on Acyclovir (Oral)

What side effects are possible with Xiclovir?

Possible Side Effects and Safety Information

The safety profile of Xiclovir (Aciclovir) is formally documented in regulatory texts, categorizing possible adverse reactions based on their frequency and the system-organ class affected. These classifications ensure a neutral, standardized communication of risk.

Commonly Documented Adverse Reactions

The most frequently reported side effects are generally gastrointestinal and neurological. These reactions, classified as Common in regulatory documents, include headache, dizziness, nausea, vomiting, diarrhea, and abdominal pains. Pruritus (itching) and various rashes are also officially noted as Common skin and subcutaneous tissue disorders.

Serious Adverse Reactions and Reversibility

Rare or Very Rare serious adverse reactions that are specifically documented include acute renal failure, hepatitis, jaundice, and severe neurotoxic events such as encephalopathy and convulsions. Official documentation notes that certain neurological adverse effects are typically reversible upon treatment cessation or normalization of drug plasma levels. Anaphylaxis and angioedema are documented as Rare immune system disorders.

Population-Specific Safety Considerations

Safety data contains specific considerations for certain populations. Older adults and individuals with renal impairment are cited as having an increased risk of developing neurological side effects, such as confusion and agitation, due to the drug's dependence on kidney function for clearance. Adequate patient hydration is consistently noted in the labeling to help mitigate the potential for renal adverse effects.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents describe the overdose profile of Xiclovir (Aciclovir) based on documented risks to the renal and central nervous systems.

Documented Manifestations and Severe Outcomes

Overdose may present with documented neurological signs, including confusion, agitation, hallucinations, tremor, and somnolence. Gastrointestinal effects such as nausea and vomiting may also be present.

The most serious outcomes involve Acute Renal Failure, which is often associated with the precipitation of aciclovir crystals in renal tubules. Severe CNS effects, including convulsions, encephalopathy, and coma, are also documented and have, in some cases, resulted in death. Patients with existing renal impairment or elderly patients are officially noted to be at an increased risk for severe neurological side effects.

Emergency Action and Management

It is officially required to seek emergency medical attention immediately for any suspected overdose. Emergency services must be contacted urgently if a person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

For management, symptomatic and supportive treatment is typically provided, and patients should be observed closely for signs of toxicity. Regulatory information confirms that no specific antidote is known. However, the substance can be significantly removed from the bloodstream via Haemodialysis, which may be considered in symptomatic cases.

Therapeutic Uses of Xiclovir

Quick Facts

  • Approved Treatment Area: Infections caused by the Herpes Simplex Virus (HSV) and Varicella Zoster Virus (VZV).
  • Main Uses: Management of conditions such as genital herpes, oral herpes (cold sores), shingles (herpes zoster), and chickenpox.
  • Treatment Goal: To help reduce the severity and duration of the viral episode, and to help suppress recurrent infections.

What Xiclovir is used for: Therapeutic Applications

Xiclovir is an antiviral compound indicated for the clinical management of infections caused by certain members of the herpesvirus family. Its primary utility is against the Herpes Simplex Virus (HSV), including type 1 and type 2, and the Varicella Zoster Virus (VZV).

Therapeutically, Xiclovir is used to address the active phases of several conditions. These applications include the treatment of initial and recurrent genital herpes episodes and oral herpes (often referred to as cold sores). It is also prescribed for the management of shingles, an acute condition caused by VZV, and for chickenpox in specific patient populations. The benefit of treatment, especially when initiated early, is to help reduce the duration and severity of the episode and its associated symptoms. Furthermore, the medicine may be used for suppressive therapy to help prevent frequent recurrence of genital herpes in eligible patients.

In addition to cutaneous and mucocutaneous infections, the intravenous formulation of this medicine is reserved for the treatment of severe systemic infections, such as herpes simplex encephalitis and disseminated herpes zoster, especially in immunocompromised patients.

Regulatory References

  1. https://www.ncbi.nlm.nih.gov/books/NBK542180/

Eligibility and Restrictions for Use

The eligibility for using Xiclovir, which contains the active substance Aciclovir, is strictly governed by officially documented regulatory rules defining who is prohibited from using the medicine and who requires conditional use.

Contraindicated and Restricted Populations

The medicine is contraindicated in patients with a demonstrated clinically significant hypersensitivity reaction to Aciclovir, its prodrug Valaciclovir, or any component of the specific formulation. This represents an absolute prohibition defined in regulatory labeling.

Population Status Eligibility Rule (Official Labeling)
Contraindicated Hypersensitivity to Aciclovir or Valaciclovir.
Conditional Use Impaired Renal Function (Dose adjustment required).
Conditional Use Older Adults (Likely reduced renal function; close monitoring required).
Conditional Use Pregnancy/Lactation (Permitted only if benefit justifies potential risk).

Eligibility extends to both adults and pediatric patients, including neonates for specific severe systemic infections, with dosing based on weight or body surface area. Patients who are dehydrated or have compromised kidney function require special caution and adjustment, as Aciclovir is eliminated primarily by the kidneys. The use in pregnant or breastfeeding women is conditional and is subject to a regulatory risk assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the clinically significant interactions of Xiclovir (Aciclovir) as documented in official regulatory labeling.

Documented Interacting Medicinal Products and Classes

The most relevant interactions relate to agents that affect the elimination of Xiclovir via the kidneys, specifically those that interfere with renal tubular secretion or possess nephrotoxic properties.

Interaction Domain Specific Interacting Agents/Classes Interaction Outcome and Constraint
Inhibition of Renal Tubular Secretion Probenecid, Cimetidine, other drugs competing for active tubular secretion. Coadministration significantly increases the half-life and AUC (systemic exposure) of Xiclovir by reducing its renal clearance. This requires caution and monitoring for potential toxicity.
Additive Nephrotoxicity Other nephrotoxic medicinal products Increased risk of renal impairment or nephrotoxicity when used concomitantly. Careful monitoring of renal function is advised, especially in patients with pre-existing kidney issues or in the elderly.
Mycophenolate Mofetil Mycophenolate Mofetil Increased plasma concentrations of both Xiclovir and the inactive metabolite of Mycophenolate Mofetil have been observed, particularly in patients with impaired kidney function. This combination requires close clinical supervision.

Interaction Profile Summary

The structure of the official interaction profile emphasizes the need for clinical vigilance when Xiclovir is combined with other medicines that impair kidney function or inhibit its elimination through renal tubules. The main constraint is the increased risk of elevated plasma concentrations and associated toxicities when such combinations are used, necessitating dose adjustment or intensive monitoring as determined by a healthcare professional.

Mechanism of Action

The core action of Xiclovir (Aciclovir) is driven by a virostatic mechanism that targets the machinery of the proliferating virus. The drug is classified as a guanosine analog, and its effect is exerted only after a necessary activation process occurs exclusively within the pathogen.


Selective Activation by Pathogen-Specific Enzyme

The mechanism is initiated by the requirement for a viral enzyme, Thymidine Kinase (vTK), which is expressed when the virus is actively replicating inside a host cell. Aciclovir acts as an inactive prodrug that must be phosphorylated by vTK as the first step in its activation cascade, ensuring the active metabolite is generated predominantly in infected cells. This process is due to the differential phosphorylation rate between viral and host enzymes, establishing the mechanism's specificity.


Obligate Termination of Viral Genetic Replication

Once fully converted to its active triphosphate form, the drug functions as a false substrate that competitively binds to and inhibits the Viral DNA Polymerase enzyme. The drug is incorporated into the growing viral DNA chain. Because it structurally lacks the necessary 3'-hydroxyl (3'-OH) group, this incorporation functionally prevents the addition of subsequent nucleotides. This chain termination prevents the formation of new viral genetic material, leading to the cessation of viral proliferation.


Constraint by Viral Latency and Enzyme Integrity

The mechanism is functionally constrained by the biological state of the virus, requiring the expression of vTK. Therefore, the mechanism is ineffective against latent virus (virus residing dormant in cells) that is not actively replicating. Furthermore, the mechanism can be overridden by mutations in the vTK or DNA polymerase genes, which prevent the initial activation step or reduce the enzyme's affinity for the active drug.

Dosage and Administration Information

Official Administration Principles of Aciclovir

Aciclovir is administered through three primary routes determined by the therapeutic context: oral (tablets, capsules, or suspension), intravenous (IV) infusion for systemic or severe infections, and topical (cream or ointment) for localized use.


Dosing and Frequency Patterns

The administration schedule follows distinct high-level patterns based on the condition being addressed. For the acute treatment of viral episodes, a frequent regimen is employed, such as 800 mg taken five times daily, often for a period of 7 to 10 days. In contrast, suppressive therapy, intended for maintenance, is typically structured around a lower-frequency schedule, such as 400 mg taken twice daily. Acute treatment must be initiated as early as possible—ideally within 72 hours of symptom onset—to align with established clinical protocols.


Administration Conditions and Adjustments

Oral formulations may be taken with or without food. A key procedural condition across all systemic routes is the requirement to maintain adequate hydration, which supports the medicine's proper clearance from the body. Intravenous administration requires the concentrated solution to be properly diluted and infused slowly over a minimum of one hour to minimize complications. Dosage adjustment is generally mandatory for patients with renal impairment, where the dose amount or frequency is modified based on the assessment of kidney function. The need for reduced dosing is also considered for older adults due to potential age-related changes in renal function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Xiclovir

Evidence for Acute Herpes Simplex Virus (HSV) Infections

The research on Xiclovir's use for managing acute genital and oral herpes episodes primarily involved short-term Randomized Controlled Trials (RCTs). These studies monitored outcomes related to time to complete healing of lesions, the rate of new lesion formation, and patient-reported outcomes describing perceived discomfort. Findings describe patterns where the groups receiving Xiclovir had measurements describing a reduced duration for the time needed to achieve complete lesion crusting compared to placebo groups. Trial data show patterns related to measurements of viral shedding at specific points during follow-up.

What remains uncertain is the long-term effect of this initial treatment on future outbreaks. Evidence is limited on whether taking Xiclovir during a first or recurrent episode may influence the frequency or severity of subsequent recurrences years later. Additionally, results for topical formulations often report only modest differences in healing time.


Evidence for Shingles (Herpes Zoster)

Xiclovir was evaluated in numerous RCTs and subsequent systematic reviews focusing on acute shingles episodes. The research explored short-term symptom changes in adults, including those in older age groups. Study outcomes examined included the time to complete healing of the zoster rash and outcomes related to physical discomfort, specifically measuring the duration and intensity of acute pain.

Studies reported measurements associated with a reduced duration for both the acute zoster rash and associated pain, particularly when administration was observed in the initial days following rash onset. However, trial findings were mixed and varied across studies regarding the drug’s observed influence on the incidence or duration of prolonged pain (Post-Herpetic Neuralgia, PHN).


Evidence for Suppressing Recurrent Genital Herpes

This research area involved long-term Randomized Controlled Trials and observational cohorts. Study outcomes examined included the proportion of patients remaining recurrence-free and the rate of asymptomatic viral shedding over extended periods. The evidence is generally consistent for the short- to intermediate-term observation of recurrence, but long-term effects regarding viral susceptibility or resistance development are not fully established, and research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Xiclovir (FAQ)


Q: Is Xiclovir considered an antibiotic?

Official documents describe Xiclovir as an antiviral medicine. It belongs to a class of drugs called purine nucleoside analogues. Therefore, it is used to slow down or stop the growth of viruses, not bacteria, which are treated by antibiotics.


Q: Is Xiclovir safe to take if I am pregnant or breastfeeding?

Official product information suggests the medicine is generally not known to be harmful when used during pregnancy. While measurable levels of the medicine pass into breast milk, this is not typically associated with adverse effects in the infant. Decisions regarding use during these times are generally made after careful review of the individual circumstance.


Q: Can Xiclovir be crushed or mixed into food?

The tablets are typically designed to be swallowed whole. However, patient information notes that if swallowing the tablet is difficult, it may be dissolved in a small amount of water and then consumed immediately.


Q: If I miss a dose of Xiclovir, what is the guidance generally described in official papers?

Official guidance describes taking the dose as soon as it is remembered. If the next scheduled dose is approaching, the guidance is generally to omit the missed dose and continue with the regular schedule. Official sources state that taking a double dose is not recommended.


Q: How is Xiclovir described regarding its use in preventing future outbreaks?

The medicine is officially indicated for the suppression of recurrent herpes simplex infections. This is often described as preventing future outbreaks by maintaining low viral activity in the body.


Q: Is Xiclovir the same kind of medicine as Acyclovir?

The drug name Xiclovir is a placeholder for the active substance Aciclovir (INN). This active substance is also widely known as Acyclovir (USAN). They refer to the same chemical compound.


Q: What is the main reason Xiclovir is prescribed?

According to official documents, the main indications include treating herpes simplex virus infections, which covers initial and recurrent genital herpes and cold sores. It is also indicated for the treatment of herpes zoster (shingles) and varicella (chickenpox).


Q: Does Xiclovir treat things other than cold sores?

Yes, official indications show that the medicine is also used to treat genital herpes infections. Furthermore, it is prescribed for systemic viral infections such as herpes zoster, commonly known as shingles, and varicella, or chickenpox.


Q: How quickly does Xiclovir start to work for viral outbreaks?

Official drug documents emphasize that for treating acute episodes, the medicine is described as being most effective when treatment is initiated as early as possible, following the initial appearance of symptoms.


Q: What happens if I stop taking Xiclovir before I finish the treatment?

Official patient information states that treatment is generally completed as prescribed, even if symptoms improve quickly. Regulatory materials note that stopping treatment too soon or skipping doses may result in the underlying infection not being fully resolved.


Q: Are there any common foods or drinks that interact with Xiclovir?

Studies cited in regulatory documents have shown that the absorption of the oral form is not significantly affected by food. Therefore, the medicine may be taken either with or without a meal.


Q: What are the most commonly reported side effects of Xiclovir?

Adverse reaction data from clinical trials and post-marketing surveillance show that commonly reported effects include headache, nausea, vomiting, diarrhea, and abdominal pain.


Q: Does Xiclovir make you drowsy or tired?

Yes, adverse reaction reports have included certain central nervous system effects such as drowsiness, lethargy, and fatigue. This is generally described as a less common or mild effect.


Q: Are there specific signs of an allergic reaction to Xiclovir that I should watch for?

The medicine is contraindicated for those with a known hypersensitivity (severe allergy) to the drug or its components. The official label lists severe reactions, such as anaphylactoid reactions, as events requiring monitoring.


Q: Is there any research looking at Xiclovir and long-term viral suppression?

Official documents reference research that supports the medicine's use for long-term suppression of recurrent infections. For patients on this suppressive therapy, the need for continued treatment is generally reassessed every six to twelve months.


Q: Is Xiclovir a medicine that cures the virus, or just controls it?

Regulatory and patient information indicates that the medicine is used to slow the growth and spread of the virus to lessen symptoms. It does not cure the infection, as it is ineffective against the dormant, latent virus that resides within the body's cells.


Q: What is the general difference between the tablet and cream forms of Xiclovir?

The oral (tablet or capsule) forms are used to treat systemic or widespread infections throughout the body and for long-term suppression. The cream or ointment forms are used topically to treat localized symptoms on the skin or mucous membranes.


Q: How long does Xiclovir stay in your system after you stop taking it?

Official pharmacokinetic information states that in adults with typical kidney function, the plasma half-life (the time it takes for half the medicine to leave the bloodstream) is approximately 3.3 hours. The drug is mainly eliminated unchanged by the kidneys.


Q: Is it normal to feel nauseous when starting Xiclovir?

Yes, nausea is listed among the commonly reported adverse effects in clinical trials and post-marketing surveillance. This is a mild, commonly reported effect.


Q: What does the box warning for Xiclovir usually talk about?

A Boxed Warning (the strongest warning issued by the FDA) is typically absent from the main prescribing information for Xiclovir in the United States.


Q: Is Xiclovir available as a generic version?

Yes, the medicine is widely available as a generic formulation. This is in addition to the availability of various original brand names.


Q: Do studies show that Xiclovir loses effectiveness over time?

Regulatory documents note that prolonged use in severely immunocompromised patients may result in the selection of virus strains that are less sensitive to the medicine. These strains may not respond to continued treatment.


Q: Does taking Xiclovir affect the results of any common lab tests?

Adverse reaction reports have included temporary changes in certain laboratory values. These changes may involve transient elevations in serum liver enzymes and changes in blood counts.


Q: Can Xiclovir be prescribed for children?

Yes, official documents provide specific dosing recommendations for the use of this medicine in children. The specific criteria and appropriate dose depend on the child’s age and the condition being addressed.


Q: Is Xiclovir considered safe for people with liver disease?

Information from authoritative sources suggests that the medicine is minimally metabolized by the liver. It has not been commonly associated with clinically apparent liver injury.


Q: What is the significance of the research evidence supporting Xiclovir's uses?

The research evidence is significant because it establishes the medicine as a standard treatment for its official indications. This is demonstrated by its inclusion on the World Health Organization's List of Essential Medicines.


Q: Can Xiclovir affect my ability to drive?

Official guidance notes that side effects such as dizziness and drowsiness are possible. Regulatory documents state that activities requiring full mental alertness, such as driving, may be affected if these side effects are experienced.


Q: Does Xiclovir contain any ingredients people are commonly sensitive to?

The medicine is contraindicated in patients with a known allergy to the drug or its components. Specific formulations may list excipients, such as milk proteins, to inform individuals with known sensitivities.


Q: What are the general rules for stopping Xiclovir treatment?

For acute treatment, official guidance describes the importance of completing the prescribed course. For long-term suppressive treatment, the need for continued therapy is generally reassessed by a healthcare professional every six to twelve months.


Q: Are there any specific activities to avoid while on Xiclovir?

Official guidance states that activities requiring full alertness may be affected if side effects like dizziness or vision impairment occur. Additionally, for genital herpes, avoiding sexual intercourse while lesions are active is generally included in patient information.


Q: Is Xiclovir considered a controlled substance?

No, the medicine is generally not classified as a controlled substance in the United States according to authoritative government sources.


Q: Do studies suggest Xiclovir is often well-tolerated?

Based on a summary of adverse event reporting, available information notes that the medicine is often well-tolerated. Reported side effects are typically mild and temporary.


Q: Are there different strengths of Xiclovir available?

Yes, the oral forms are typically available in strengths such as 200 mg, 400 mg, and 800 mg. It is also available in various formulations, including suspension, cream, and injectable forms.


Q: What is the typical time frame for the expected duration of Xiclovir treatment?

The duration depends on the infection being treated. For acute viral infections, the typical duration is 5 to 10 days. Suppressive therapy, used for prevention, may last for an extended period.


Q: Do patients often report stomach upset with Xiclovir?

Yes, stomach upset, including nausea, vomiting, and abdominal pain, is listed among the commonly reported adverse effects in the official product information.

How should Xiclovir be stored and disposed of?

How to Store and Dispose of Xiclovir (Aciclovir)

Official regulatory information dictates strict rules for the storage and disposal of Aciclovir formulations.

Oral tablets and capsules must be stored at controlled room temperature, generally 15 C to 25 C (59 F to 77 F), and must be protected from moisture and direct light. The container must be kept tightly closed, and the medicine should not be frozen.

Condition Requirement
Temperature Controlled room temperature
Protection Keep from moisture and direct light
Child Safety Store out of the sight and reach of children
Prohibited Do not freeze; do not store in the bathroom

All forms must be stored out of the sight and reach of children. Expired or unused medicine must be thrown away according to official disposal guidelines and local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xiclovir found in:

A-Z Index: